Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8621826 | 0.87 | ESR1 (0.33) | ESR1ESR2 | |
| SCHEMBL2780203 | 0.82 | — | — | |
| SCHEMBL2636314 | 0.79 | — | — | |
| SCHEMBL4730525 | 0.79 | ESR1 (0.36) | ESR1ESR2 | |
| SCHEMBL7593649 | 0.79 | ESR1 (0.34) | ESR1ESR2 | |
| SCHEMBL4729293 | 0.79 | ESR1 (0.34) | ESR1ESR2 | |
| SCHEMBL7551581 | 0.79 | ESR1 (0.34) | ESR1ESR2 | |
| SCHEMBL9578948 | 0.79 | CES1 (0.47) | ESR1ESR2 | |
| SCHEMBL19578784 | 0.79 | CES1 (0.47) | ESR1ESR2 | |
| SCHEMBL4728017 | 0.79 | ESR1 (0.36) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111377997-A | Preparation method of fulvestrant related substance | 江苏豪森药业集团有限公司 | 2020-07-07 | — | — | CN | disclosed |
| US-20100174101-A1 | Process for the manufacture of 7-alpha-[9-(4,4,5,5,5-penta fluoropentylsulphinyl) nonyl]estra-1,3,5-(10)- triene-3,17-beta-diol | XI'AN LIBAND PHARMACEUTICAL CO., LTD. (CN) | 2010-07-08 | — | — | US | disclosed |
| US-20100174101-A1 | Process for the manufacture of 7-alpha-[9-(4,4,5,5,5-penta fluoropentylsulphinyl) nonyl]estra-1,3,5-(10)- triene-3,17-beta-diol | XI'AN LIBAND PHARMACEUTICAL CO., LTD. (CN) | 2010-07-08 | — | — | US | disclosed |
| US-20100105934-A1 | FULVESTRANT INTERMEDIATE | SYNTHON BV (NL) | 2010-04-29 | — | — | US | disclosed |
| WO-2010043404-A1 | PROCESSES AND INTERMEDIATES FOR THE PRODUCTION OF FULVESTRANT | SYNTHON B.V. (NL) | 2010-04-22 | — | — | WO | disclosed |
| US-20070142345-A1 | Steroids for cancer treatment | INNOVENTUS PROJECT AB (SE) | 2007-06-21 | — | — | US | disclosed |
| US-20070142345-A1 | Steroids for cancer treatment | INNOVENTUS PROJECT AB (SE) | 2007-06-21 | — | — | US | disclosed |
| US-20070142345-A1 | Steroids for cancer treatment | INNOVENTUS PROJECT AB (SE) | 2007-06-21 | — | — | US | disclosed |
| EP-1716166-A2 | 17-METHYLENE- OR 17-SPIRO-CYCLOPROPANE 7-SUBSTITUTED ESTRA-1,3,5(10)-TRIENE DERIVATIVES WITH ANTI-ESTROGENIC ACTIVITY | Innoventus Project AB (SE) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005077968-A2 | 17-METHYLENE-OR 17 - SPIRO - CYCLOPROPANE 7 - SUBSTITUTED ESTRA - 1, 3, 5 (10) - TRIENE DERIVATIVES WITH ANTI - ESTROGENIC ACTIVITY | INNOVENTUS PROJECT AB (SE) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105934-A1 | FULVESTRANT INTERMEDIATE | CYP19A1, NR5A1, HSD17B11 | ESR1 8/4885ESR2 5/4885 |
| US-20100174101-A1 | Process for the manufacture of 7-alpha-[9-(4,4,5,5,5-penta fluoropentylsulphinyl) nonyl]estra-1,3,5-(10)- triene-3,17-beta-diol | CYP19A1, HSD17B11, CYP17A1 | ESR1 24/4885ESR2 15/4885 |
| US-20070142345-A1 | Steroids for cancer treatment | HSD17B11, ESRRB, ESRRA | ESR1 9/4885ESR2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.